Betting on biotech

| Print |  Email
Articles - May 2013
Monday, April 29, 2013

BY PETER BARNES

0513 FOB Conversation MedicalResearch
Jennifer Fox, executive director of OTRADI, in the soon-to-be-completed South Waterfront bioscience incubator.
// Adam Wickham

A South Carolina native, biologist Jennifer Fox, Ph.D., followed research opportunities to Tulane University, Northwestern and, eventually, the University of Oregon, where her work focused on drug resistance in breast cancer. In 2008 she moved to the Oregon Translational Research and Development Institute (OTRADI), a nonprofit that helps scientists fund and execute advanced bioscience research. Now, as OTRADI’s new executive director, 39-year-old Fox will oversee a 13,000-square-foot business incubator hosting startups like Aronora, a researcher of cardiovascular drugs, and AbSci, which is developing an antibody production technology. Oregon Business caught up with Fox as the organization prepared to move into its new space in Portland’s South Waterfront district. There OTRADI hopes to entice more venture capital in a sector known for its robust growth and high-paying jobs.

OB: Commercial real estate firm Jones Lang LaSalle recently ranked U.S. regions with the largest bioscience presence. Seattle came in 10th. No Oregon city made the list. What makes Portland a good place for investment in this field?

Major research universities and talent. We have a place like OHSU that’s one of the largest employers in Portland and has a great deal of grant funding for research products. If we don’t create the kind of ecosystem that fosters that and keeps that within the state, we see what’s happened in the past — a product gets to a certain stage and then gets pulled down to California or up to Seattle.

OB: Why is that?

It takes so long for them to get products through the FDA approval process — about 12 years from start to stop to get from an idea to a drug stage, and they say $30 million on average. A lot of times companies — Aronora is a good example — get a product to a certain position by writing their own grants. But you get to the stage they call the “valley of death,” where you need a great deal more money and deeper pockets to get the drug all the way through the approval process. That’s when you partner with, perhaps, a larger company. That’s something we can help them do as well.

OB: Other industries already benefit from business accelerators hosted by Oregon universities, nonprofits and even Nike. What other resources unique to bioscience companies will OTRADI offer?

Our incubator is going to have specialized equipment for bioscience, which is cost limiting to a small bioscience company. You’re not going to want to build out your own laboratory with a fume hood and a tissue-culture hood and giant robots and machinery that you might need to get the work done. We will have that available in the shared facility, and have people here with the expertise to teach people how to use these pieces of equipment.

OB: What supporting industries could also benefit from a growing bioscience cluster?

In Oregon people would say our main strength is medical-device technologies or diagnostics. And those aren’t pharmaceutical drugs; those are actual you-can-put-your-hands-on-them products. So you could have materials. You could have medicinal chemistry. You’ve got companies across the state that are working on the reagents and the ingredients that scientists use to promote their research, and they like to be near companies that are engaged in this.

OB: Do you ever miss working in the lab now that you’re surrounded by emerging companies and promising research?

I do miss my research. But the great thing about working at OTRADI is having a new line on different topics and different areas all the time. Someone might come in who’s interested in cancer, or hormone signaling, or endocrine disruption, or anything that I’ve done in my past, and it’s great. But someone might come in with something completely new. It’s a challenge and it’s been great. It’s never boring.

 

More Articles

House of Clarity

July/August 2015
Monday, July 13, 2015
BY JACOB PALMER

Holding a Power Lunch at Veritable Quandary in downtown Portland.


Read more...

Storyteller in Chief: Natural Prophets

July/August 2015
Monday, July 13, 2015
BY SAM BLACKMAN

Storyteller-in-chief with the CEO and co-founder of Elemental Technologies.


Read more...

Downtime with Debra Ringold

July/August 2015
Monday, July 13, 2015
BY JACOB PALMER

Dean of the Atkinson Graduate School of Management, Willamette University


Read more...

Oregon needs a Grand Bargain energy plan

Linda Baker
Monday, June 22, 2015
0622-gastaxblogthumbBY LINDA BAKER

The Clean Fuels/gas tax trade off will go down in history as another disjointed, on-again off-again approach to city and state lawmaking.


Read more...

The 5 highest revenue-generating parks in Oregon

The Latest
Thursday, June 11, 2015
parksthumbBY JACOB PALMER | DIGITAL NEWS EDITOR

In 2014, total revenue for camping and day use in Oregon State Parks was a little more than $17 million. That figure may even higher this year "because we've had exceptionally nice weather," Hughes says.


Read more...

Apartment Mania

Guest Blog
Thursday, June 18, 2015
4805983977 11466ce1d6 zBY BRAD HOULE | CFA

While most categories of commercial real estate have performed well, one of the most robust has been apartment buildings.


Read more...

6 key things to know about summer baseball in Oregon

The Latest
Friday, June 05, 2015
basedthumbBY JACOB PALMER | DIGITAL NEWS EDITOR

As temperatures in Oregon creep into the 90s this weekend, Oregonians' thoughts are turning to — summer baseball.


Read more...
Oregon Business magazinetitle-sponsored-links-02
SPONSORED LINKS